EP4704906A2 - Aptamerbasierte verzögerte freisetzung von therapeutika - Google Patents
Aptamerbasierte verzögerte freisetzung von therapeutikaInfo
- Publication number
- EP4704906A2 EP4704906A2 EP24797736.6A EP24797736A EP4704906A2 EP 4704906 A2 EP4704906 A2 EP 4704906A2 EP 24797736 A EP24797736 A EP 24797736A EP 4704906 A2 EP4704906 A2 EP 4704906A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- aptamer
- less
- molecular payload
- certain embodiments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363461525P | 2023-04-24 | 2023-04-24 | |
| PCT/US2024/025776 WO2024226465A2 (en) | 2023-04-24 | 2024-04-23 | Aptamer-based sustained release of therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4704906A2 true EP4704906A2 (de) | 2026-03-11 |
Family
ID=93257382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24797736.6A Pending EP4704906A2 (de) | 2023-04-24 | 2024-04-23 | Aptamerbasierte verzögerte freisetzung von therapeutika |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4704906A2 (de) |
| WO (1) | WO2024226465A2 (de) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120141551A1 (en) * | 2010-12-02 | 2012-06-07 | Ecosynthetix Ltd. | Aptamer bioconjugate drug delivery device |
-
2024
- 2024-04-23 WO PCT/US2024/025776 patent/WO2024226465A2/en not_active Ceased
- 2024-04-23 EP EP24797736.6A patent/EP4704906A2/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024226465A2 (en) | 2024-10-31 |
| WO2024226465A3 (en) | 2024-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8853177B2 (en) | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto | |
| EP2021008B1 (de) | Stabilisierte immunmodulatorische rna (simra) verbindungen für tlr7 und tlr8 | |
| WO2011005942A2 (en) | Oligonucleotide-based compounds as inhibitors of toll-like receptors | |
| WO2023051822A1 (zh) | 用于治疗与pcsk9相关疾病的靶向寡核苷酸 | |
| US12582668B2 (en) | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) | |
| WO2010141483A2 (en) | Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9 | |
| JP7829478B2 (ja) | Apoc3関連疾患および障害の処置のための方法 | |
| EP2588143B1 (de) | Neuartige agonisten des toll-like-rezeptors 3 und verfahren zu deren verwendung | |
| CN110036019A (zh) | 用于治疗多囊肾病的修饰的低聚核苷酸 | |
| US20220315927A1 (en) | Modulators of yap1 expression | |
| TW202442241A (zh) | 用於治療多囊性腎病之方法 | |
| US20250135013A1 (en) | Targeting Oncogenic KRAS with Molecular Brush-Conjugated Antisense Oligonucleotide | |
| CN112996568A (zh) | 用于调节mir-10b活性的微小rna化合物和方法 | |
| EP4704906A2 (de) | Aptamerbasierte verzögerte freisetzung von therapeutika | |
| AU2023317359A1 (en) | DRY EYE THERAPEUTIC AGENT CONTAINING DNA OLIGONUCLEOTIDE THAT SELECTIVELY BINDS TO IFN-γ | |
| WO2017136399A1 (en) | POTENTIATION OF mmRNA THERAPEUTICS | |
| HK1127727B (en) | Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8 | |
| JP2003513894A (ja) | プロドラッグ効力の増強 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20251110 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |